Remus Pharmaceuticals bonus share history
NSE: REMUSPharmaceuticals & Biotechnology
Last close ₹880.60down ₹20.60 (2.29%)
Share price at the NSE close on 23 Oct 2026. Previous close ₹901.20.
52-week range of traded prices to 23 Oct 2026
₹580.00Low, 9 Mar 2026₹1,039.00High, 15 Oct 2026
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price.
- ₹1,038 Cr
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. The filing of 20 May 2026
- 28.1
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 20 May 2026
- 3.0
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.11%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it. The filing of 20 May 2026
- 12.2%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 20 May 2026
- 13.1%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 20 May 2026
- 0.06
- Volume, NSEVolume. Shares traded on the last trading day.
- 2,800
What one share became
Bonus issues and splits since listing in May 2023. Neither changes what a holding is worth on the day.Remus Pharmaceuticals dividend history
One share held before 6 Jun 20248 shares todayShares today for one share held before. One share multiplied by the share factor of this bonus or split and of every one after it: a 1:1 bonus doubles the count, and a split of a ₹10 share into ₹2 shares multiplies it by five.
- Face value today
- ₹10
- Bonus issues
- 2
Bonus issues: ratio, ex-date and record date
A bonus issue gives holders free extra shares in a fixed ratio. On record from 2007.
Shares today for one held before the ex-date, after every event sinceShares today for one share held before. One share multiplied by the share factor of this bonus or split and of every one after it: a 1:1 bonus doubles the count, and a split of a ₹10 share into ₹2 shares multiplies it by five.
- 4 Jul 2025 · ex-date1 for 1 bonusRecord date 4 Jul 20252 shares todayfor 1 held before 4 Jul 2025
- 6 Jun 2024 · ex-date3 for 1 bonusRecord date 6 Jun 20248 shares todayfor 1 held before 6 Jun 2024